Research Articles

Effectivity of Annona Muricata and Artemisinin Combined Therapy On Brain CXCL10 Expression

Abdulhakim Sulayman A. A., Kis Djamiatun1,2*, Muflihatul Muniroh3

1Biomedical Science program, Faculty of Medicine Diponegoro University, Semarang, Indonesia
2Departament of Parasitology, Faculty of Medicine, Universitas Sumatera Utara, Indonesia
3Departement of Physiology, Faculty of Medicine, Universitas Indonesia, Indonesia

Abstract

Background: Malaria, caused by Plasmodium spp infection, is a major global cause of morbidity and mortality. Most experimental cerebral malaria (ECM) studies show increase number of Th1 cells and CTLs in the brain, due to increase chemokine expression, including CXCL10, a potent chemokine involved in cerebral malaria (CM). Recent studies show that CXCL10 provokes apoptosis of human brain micro-endothelial cells and in vitro neuroglia cells.

Objective: To determine whether combination of Annona muricata-leaf-extracted-bywater (AME) and artemisinin-combination-therapy (ACT) reduce brain-CXCL10-expression of Swiss-mice inoculated with P. berghei ANKA (PbA).

Methods: This was an experimental-study with post-test-only-control-group-design. Twenty-four Swiss-mice (PbA-inoculated) were randomly divided into 4 groups. Control group (C) was PbA inoculated only. X1, X2 and X3 groups received AME, ACT and combination of AME and ACT treatment, respectively. CXCL10 was stained with in immunohistochemistry, which then observed by light microscope in order to determine Allred-score. Kruskal-Wallis test was used to statistically analyze the differences among groups, then followed by a Mann-Whitney U test.

Result: C and X1 groups had severe-PbA-infection when the study was end on day-7-PbA-infection, while X2 and X3 groups entered recovery-stage. The AME-ACT-treatment-group had significantly lower of brain-CXCL10-expression than AME-group (p=0.008) and nearly significantly lower than control-group (p=0.058). Group that received ACT alone had no different value of brain-CXCL10-expression than control-group (p=0.502) and combination AME–ACT group (p=0.335).

Conclusion: The combination of AME–ACT treatment decreases brain-CXCL10-expression of Swiss-mice during PbA-infection-recovery-stage, indicating the effectivity of AME–ACT combined therapy is better prevention of cerebral malaria than AME alone..

Keywords: Annona muricata, Artemisinin, P. berghei ANKA, CXCL10

Permalink/DOI: https://doi.org/10.14710/jbtr.v5i2.4802

INTRODUCTION

Malaria, caused by Plasmodium spp infection that is transmitted by mosquitoes, is a major global cause of morbidity and mortality. Plasmodium spp life cycle in the vertebrate host are including a clinically silent early stage in the liver. Followed by erythrocytic stage, which is responsible for the pathology of malaria.

Malaria in patients may be caused by P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi while some species of Plasmodium that infects animal, but not humans, are available for laboratory studies, including P. berghei ANKA (PbA) which allows the dissection of immune mechanisms of protection and pathology.

Severe malaria including cerebral malaria might be fatal. Susceptible mice infected with PbA develop experimental cerebral malaria (ECM). Most ECM study...
using C57BL6 mice showed that increase number of Th1 cells and CTLs in the brain. These cells migrate to brain due to chemokines. Increase levels of chemokine levels are widely associated with cerebral malaria (CM). The most potent chemokines involved in CM are those that bind to the C-X-C motif 3 receptor (CXCR3), including CXCL9, and CXCL10. CXCL10 binding to high affinity CXCR3, is the first known chemokine that can direct the activated CD4+ and CD8+ T-cells, natural killer (NK) cells and natural killer T (NKT) cells. The importance of CXCL10 has been suggested by several studies on malaria. A study on CM in Ghanaian children shows that of 36 biomarkers, only CXCL10 is an independent serum marker associated with CM death. In addition, studies of cerebral spinal fluid (CSF) of CM patients show that CXCL10 is one of eight biomarkers significantly related with CM. The ECM study in C57BL6 mice shows that CXCL10 is highly induced in the brain especially in infected mouse neurons of PbA. Interestingly CXCL10-deficient mice are protected in part from ECM death.

Recent study shows that CXCL10 provokes apoptosis of human brain microendothelial cells and neuroglia cells in vitro. In contrast to those found in CM and ECM studies, in vitro study on astrocytes shows a reduced CXCL10 expression during hypoglycemia and hypoxia which are two conditions found in severe malaria. Astrocytes are important in maintaining brain homeostasis and preventing brain inflammation caused by T cells. CXCL10 is expressed by many brain-cell including astrocytes. The production of CXCL10 by astrocytes is consistent with the detection of in situ CXCL10 mRNA in astrocytes during malaria infection. The mechanisms underlying the different CXCL10 production in this model may be due to the relative magnitudes of microbial signals versus cytokine, such as IFN-γ. Most recent study shows that CXCL10 expression in the brain of severe-PbA-infected Swiss mice is modulated by ethanolic leaf extract of *Annona muricata*. Parasitaemia, however is not affected by this extract. Additionally, it has not been studied before whether artemisinin combination therapy (ACT), anti-malaria standard therapy commonly used, affect CXCL10 expressed by astrocyte during severe malaria. Therefore it is interesting to study the influence of combination of this herb and ACT toward CXCL10 expressed by astrocytes of Swiss mice during severe malaria.

After the emergence of widespread drug resistance to chloroquine and sulfadoxine-pyrimethamine, ACT is introduced as a highly effective treatment for uncomplicated malaria (caused by *P. falciparum* and *P. vivax*), preventing the progression of severe illness and death. The first-line treatment recommended by WHO for uncomplicated falciparum malaria in almost all endemic countries is ACT. Funding for ACT procurement has increased rapidly and is now widely available from several manufacturers and in many formulations. Between year of 2003 and 2007, almost all countries in Africa changed their treatment policy to ACT as a first-line treatment of uncomplicated malaria, and since then, ACT procurement and distribution increase remarkably.

*Annonaceae* comprising about 123 genera and 2,100 species, is draw attention because of their traditional use of malaria. The anti-malarial treatment of *Annona muricata* leaf extract (AME) is demonstrated in vivo by using mice inoculated with PbA. The CM study showed that tumor necrosis factor-alpha (TNF-α), a proinflammatory cytokine, contributed to the pathogenesis of CM. Ethanolic-AME treatment is associated with decreased TNF-α and nitric oxide (NO) produced by splenocytes from Swiss inoculated with PbA as a model for ECM. Water extract of *A. muricata* leaves is available in the market, this therefore it is interesting to focus a study in the combination of this herb and ACT an anti-malaria therapy used in Indonesia. The purpose of this research is to determine whether a combination of *Annona muricata* and ACT reduces CXCL10 expressed by astrocytes in the brain of Swiss albino mice inoculated with PbA.

**Materials and Methods**

This study was experimental study, by using randomized post test only control group design. PbA-mouse donor was purchased from Parasitology Department Universitas Gajah Mada. The PbA-infection was done by intra peritoneal injection of 10^7 parasitized-red blood cells (pRBCs) in 0.2 ml solution to all experimental mice used in this study. The treatment used was *A. muricata* leaf-extracted using water (AME), ACT and combination both of AME and ACT. AME was obtained for free from SudoMuncul-company. AME was obtained from *A. muricata* leaves which were sorted, washed and dried. Percolation was then done by using water at 60°C for two hours; subsequently evaporation was done in 60°C temperature. The filler was then added to the wet granulation of *A. muricata* leaf-extract. The next was oven dried the granules and then milled them. Finally the AME was ready to use. ACT used in this study was Dihydroartemisinin Piperaquine (DHP). The DHP dose for malaria patients was adjusted for PbA-infected mice. The calculation of ACT dose used was 0.546 multiply by (mouse body-weight (BW) divided by 20).

This study used 24 female-Swiss albino mice, which were purchased from the private animal breeding at Bandung (certified by Food and Agriculture Department of Bandung City Government). The mice were grouped in four and were PbA inoculated. Control (C) group was PbA-inoculated only and did not receive any treatment, while X1, X2 and X3 groups were treated with AME, ACT and combination of AME and ACT. AME-prevention dose of 4.68mg/ 30g mice-weight was given for 7 days before PbA-infection which then continued until day 3 PbA-infection. AME-therapeutic dose of 9.36mg/ 30g mice-weight was then administered until day 6 PbA-infection. ACT dose used was 0.819mg/ 30g mice-weight which administer since day 4 until day 6 PbA-infection. All mice were terminated on day 7 PbA-infection. The animals were housed in Parasitology Department, Faculty of Medicine Diponegoro University. This study had been approved by the medical research ethics committee, Faculty of Medicine Diponegoro University- RSUP Dr. Kariadi Semarang with No. 86/EC/H/RF-RSDK/XII/2017. This study was a continuation of our previous study which evaluated the parasitaemia and number of lymphocytes at the brain perivascular in severe malaria infection. The brains were collected from all groups for CXCL10-expression study.
CXCL10 expression was stained by using IHC method, and was evaluated based on Allred score which were determined by two experts from Pathology Anatomy Department Faculty of Medicine Diponegoro University, Semarang, Indonesia. Because of the CXCL10 data were not homogen and not distributed normally, statistical analysis used was Kruskal-Wallis test and then followed by Mann-Whitney U test.

RESULTS
Parasitaemia level was observed at day 3 and 7 post inoculation (p.i). All groups were positive of PbA-infection at day 3 p.i. The mean parasitaemia at day 7 p.i of C and X3 groups were 19.88% and 18.40%, while those of X2 and X3 groups were 0.55% and 0.41%. Those of C and X3 groups indicated severe-PbA-infection at day 7 p.i. X2 and X3 groups entered recovery-phase of PbA-infection as indicated by very low parasitaemia. No difference in parasitaemia level at day 7 p.i was found between either C and X3 groups or X2 and X3 groups (Mann-Whitney U test; p > 0.05).

The IHC showed the different proportions and intensity of CXCL10 expression in the cytoplasmic cells in the brain (Figure 1). The higher the proportion and intensity is showed with slightly hematoxylin (blue).

**Figure 1.** IHC of brain-CXCL10 used to determine Allred score

Allred score = proportion score + intensity score. A= Proportion ≤ 1/100 colored cell (score 1); B= Proportion ≤ 1/10 colored cell (score 2); C= Proportion ≤ 1/3 colored cell (score 3); D=Proportion ≤ 2/3 colored cell (score 4); E= Proportion all cells are coloured(score 5); F=Intensity (-) (score 0); G=Weak Intensity (score 1); H= Moderate Intensity (score 2); I= Strong Intensity (score 3).

Statistical analysis indicated that CXCL10 Allred score was normally distributed in all studied group. Analysis of variance, however, showed that the data were not homogen (p=0.015), therefore, Kruskal-Wallis test was performed. This test showed that CXCL10 expression was significantly different among the studied groups (p = 0.011). Then Mann-Whitney U test was performed to see the difference of CXCL10 expressions between two groups (see Table 1). The X3 group expressed significantly higher CXCL10 than C (p = 0.022), X2 (p = 0.017) and X3 (p = 0.008) groups. The CXCL10 expression of X3 group was lower than C group, but the difference was not significant (p = 0.058).

**Figure 2.** Graph Box plot was Allred score of brain-CXCL10-expression.
All mice used were PbA-infected, and were divided in four groups which were C group: without any treatment; X1 group: treated with AME; X2 group: treated with ACT; Group X3: treated with AME and ACT.

The brain-CXCL10 expressions in Swiss Mice

Allred score was determined based on the calculation both proportion and intensity scores (Figure 1). Kappa test was done to identify the similarity of the two assessors to determine Allred score of CXCL10-expression on the same area of the IHC-slide. This test indicated a moderate agreement between the two assessors (Kappa value = 0.6). The CXCL10-expression of X3 group was higher than other groups (C, X2 and X3 groups) (Figure 2).
Additionally, X2 and X3 groups showed no difference of CXCL10-expression (p = 0.335).

**DISCUSSION**

The present study showed that the X1 group which received water extract of *Annona muricata* leaves had significant higher CXCL10 expression in the brain than C group (PbA-infected only) (Table 2). This occurred during severe PbA infection in both C and X1 groups. All together suggest that water extract of *Annona muricata* leaves associates with the increase the brain-CXCL10-expression of Swiss mice during severe PbA-infection. This finding is in line with previous study using ethanolic extract of *Annona muricata* leaves. The ethanolic extract of *Annona muricata* leaves in dose of 100 mg/Kg BW/day for total period of 14 days increases the brain-CXCL10-expression in severe PbA infected Swiss mice. The present study showed that the brain-CXCL10 expression of X2 and X3 group was not different than C-group. Both of X2 and X3 groups had very low parasitaemia level indicating that they were entering recovery stage. This suggests that the low parasitaemia shows no observable influence on the brain-CXCL10-expression during recovery stage of PbA-infection. This present finding was not as expected before. The previous study showed that the brain-CXCL10-expression in controls with severe PbA infection was significantly lower than healthy control groups. This indicates that the brain-CXCL10 expression associates with severe PbA infection when the highest parasitaemia levels occur.

The groups that received ACT and AME-ACT-combination showed comparable brain-CXCL10 expression on day 7 PbA-infection (Table 1). This was in line with the study comparing artemether (ART) alone and the combination of ART and immunomodulator treatment, showing that CXCL10 of those treated groups was not different in day 11 PbA-infection. Parasitaemia percentage was significantly lower in those of treated either ACT or AME-ACT-combination than control group. This indicates that the relation between brain-CXCL10-expression and parasitaemia percentage in treated groups is different than that of controls. Brain-CXCL10-expression in those treated groups might relate to the re-convalescent phase of severe PbA-infection, while those in positive controls might relate to the immunopathological condition. This was supported in some part by study observing parasitaemia and CXCL10 expression. The previous study using PbA-infected C57BL/6J, showed lower parasitaemia percentage in those treated groups (either ART or combination ART-immunomodulator) than that of day 11 PbA-infected-control group. Reduce CXCL10 expression and parasitaemia occurred at the same time in those treated groups. This indicates that decrease CXCL10 expression comes about at the recovery phase of PbA-infection. Brain-CXCL10 expressed in the control-group in the present study, however was not in line with previous study showed that brain-CXCL10 mRNAs of day 11 PbA-infected control group were significantly higher than those receiving treatments. Because of the difference of mouse-strain used and method used to evaluate a CXCL10 expression, the previous finding was different than ours. The Kappa value of 0.6 on the Allred score of CXCL10 expression indicates that the CXCL10 mRNA examination or CXCL10 IHC examination using more advanced methods are needed to provide more accurate information.

Among many cell types in the brain, astrocytes express CXCL10 at the latest stage of infection. Other infectious disease induce an increase CXCL10 expressed by astrocytes, which are the main CXCL10 source in CNS. Our study might complete with evaluation IHC of glial fibrillary acidic protein (GFAP) as active-astrocyte-biomarker. Many factors may influence astrocyte-CXCL10 expression in the brain of those with malaria. Apoptotic-astrocytes were found in PbA-inoculated C57BL/6 mice, and reduce astrocyte-CXCL10-expression was found in the condition of hypoxia and hypoglycemia, which were both presents in severe malaria. Whether these factors influence astrocyte-CXCL10-expression in the present study are needed to be further evaluated.

It remains a hope that AME-ACT-combination protects severe malaria. Lower brain-CXCL10-expression found in during recovery stage of PbA-infected Swiss-mice treated with AME-ACT-combination than the PbA-infected-controls (Table 2). This was almost statistically different (p = 0.058), therefore additional protective and pathologic marker should be assessed. CXCL10 has immunopathologic effect in malaria. CXCL10 levels were higher in the cerebrospinal fluid of CM patients, and those in plasma correlate with mortality of those patients. Genetic CXCL10-polymorphism relates to higher CXCL10 plasma is associated with CM susceptibility. This may be explained by study shows that CXCL10 is capable to induce apoptosis of neuroglia. CXCL10 may not be the only pathologic factor. Both pRBCs and their soluble factors induce apoptosis of vascular endothelial cells and neuroglia. Therefore, it is warrant to be evaluated that a reduce brain-CXCL10-expression found in group treated

| Groups | CXCL10 expression median (min-max) | p       |
|--------|-----------------------------------|---------|
|        |                                   | X1      | X2      | X3      |
| Control| 6.00 (6.00 – 6.00)                | 0.022*  | 0.502   | 0.058   |
| X1     | 6.75 (6.00 – 8.00)                | (-)     | 0.017*  | 0.008*  |
| X2     | 5.75 (4.00 – 7.00)                | (-)     | 0.335   |         |
| X3     | 5.33 (4.00 – 8.00)                | (-)     |         |         |

* Mann-Whitney U test with significant difference (p < 0.05)
with ACT-AME-combination reduces neuronal apoptosis during recovery phase of PbA-infected-Swiss mice.

AME treatment associates with a significant increase brain-CXCL10-expression during severe-PbA-infection (Table 2). Based on astrocyte studies, the protective effect of AME treatment in severe malaria stays possible. Astrocytes are important cells to limit central nervous system (CNS) inflammation induced by T-cells. By releasing CXCL10, astrocytes attract Th1-cells expressing CXCR3, the receptor of CXCL10. Beside that astrocytes are able to suppress the activation, proliferation, and function of Th1-cells. The AME beneficial for those with severe malaria needs to be evaluated in further studies. Whether any association between increase astrocyte-CXCL10-expression and reduce function of Th1-cells is found in AME-treatment of severe PbA infection. Additionally, whether a reduced astrocyte-CXCL10-expression associates with a reduced function of Th1-cells in the recovery stage of PbA-infection in Swiss mice treated with combination of AME-ACT. A difference of CXCL10 expressed by astrocytes was found in a virus-infection susceptible and resistant mouse. The present study evaluated the effect of AME and ACT in PbA severely infected Swiss mice which were ECM susceptible mice. Evidence in this present study, therefore, is completed by comparing the ECM-susceptible and resistant mice.

The evaluation of TLRs and CTLA expressed by astrocytes would enrich the present study. Astrocytes express TLR2 and TLR4. Astrocytes would enrich the present study. Astrocytes were ECM suscept. of AME and ACT in PbA severely infected Swiss mice.

**CONCLUSION**

The combination of Annona muricata leaf extract (AME) and artemisinin combined therapy (ACT) lowers brain-CXCL10-expression more than AME alone.

**REFERENCES**

1. Plewes, K., Leopold, S.J., Kingston, H.W.F., Dondorp, A.M. (2019). Malaria: What’s New in the Management of Malaria? Infect Dis Clin North Am, 33 (1):39-60.

2. Bakniwewa, S.M., Weiser, S., Grey, M., Heng, B., Guillemin, G.J., Ball, H.J., Hunt, N.H. (2016). Synergistic induction of CXCL10 by interferon-gamma and lymphotoxin-alpha in astrocytes: Possible role in cerebral malaria. Cytokine, 78:79-86.

3. Villegas-Mendez, A., Greig, R., Shaw, T., de Souza, B., Gwyer Findlay, E., Stumhofer, J., Hafalla, J.C., G Blount, D., A Hunter, C., M Riley, E., N Couper, K. (2012). IFN-gamma-Producing CD4(+) T Cells Promote Experimental Cerebral Malaria by Modulating CD8(+) T Cell Accumulation within the Brain. J Immunol, 189: 968-979.

4. Campanella, G.S., Tager, A.M., El Khoury, J.K. (2008). Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc Natl Acad Sci USA, 105: 4814.

5. Armah, H.B., Wilson, N.O., Sarfo, B.Y. (2007). Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar J, 6: 147-163.

6. Wilson, N.O., Solomon, W., Anderson, L. (2013). Pharmacologic inhibition of CXCL10 in combination with anti-malaria therapy eliminates mortality associated with murine model of cerebral malaria. PloS One, 8: e60898.

7. Bakniwewa, S.M. (2015). The Astrocyte: a Crossroads in Cerebral Malaria Pathogenesis. Ph.D. Dissertation, Discipline of Pathology School of Medical Sciences Faculty of Medicine, University of Sydney.

8. Gimsa, U., Mitchison, N.A., Brunner-Weinzierl, M.C. (2013). Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediators Inflamm, 2013: 1-11.

9. Djamiutun, K., Matug, S.M.A., Awal Prasetyo. (2017). Annona muricata modulate brain-CXCL10 expression during cerebral malaria phase. Series: Earth and Environmental Science, 55: 2-12.

10. Sinclair, D., Zani, B., Donegan, S. (2009). Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev, 3: CD007483.

11. WHO (2009). World malaria report. Geneva: World Health Organization.

12. WHO (2014). World malaria report. Geneva: World Health Organization.

13. Mabberley, D.J. eds. (2008). Plant Families: A Visual Dictionary, 3rd edition. Cambridge University Press.

14. Somsak, V., Polwiang, N., Somsak, V., Polwiang, N., Chachiyo, S. (2016). Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev, 3: CD007483.

15. Zhu, X., Liu, J., Feng, Y., Pang, W., Qi, Z., Jiang, Y., Shang, H., Cao, Y. (2015). Phenylhydrazine administration accelerates the development of experimental cerebral malaria. Exp parasitol, 156: 1-11.
16. Karolina, M.E., Fransisca Prameshinta, H., Dharmana, E., Djamiatun, K. (2016). Efektivitas Ekstrak Daun Sirsak (Annona Muricata) dalam Menurunkan Kadar TNFα dan Meningkatkan Kadar NO Uji Coba pada Mencit Swiss yang Diinokulasi Plasmodium Berghei ANKA. Jurnal Kedokteran Brawijaya, 29:4.

17. Chai, Q., She, R., Huang, Y., Fu, Z. F. (2015). Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells, production of chemokines and cytokines, and enhancement of blood-brain barrier permeability. J Virol, 89: 870-6.

18. Yamano, Y., Coler-Reilly, A. (2017). HTLV-1 induces a Th1-like state in CD4(+) CCR4(+) T cells that produces an inflammatory positive feedback loop via astrocytes in HAM/TSP. J Neuroimmunol, 304: 51-55.

19. Bakmiwewa. (2015).The Astrocyte: a Crossroads in Cerebral Malaria Pathogenesis. Doctor of Philosophy, Pathology School of Medical Sciences Faculty of Medicine, University of Sydney.

20. Jain, V., Armah, H. B., Tongren, J. E., Ned, R. M., Wilson, N. O., Crawford, S., Joel, P. K., Singh, M. P., Naggal, A. C., Dash, A. P., Udhayakumar, V., Singh, N., Stiles, J. K. (2008). Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malar J, 7: 83.

21. Wilson, N., Driss, A., Solomon, W., Dickinson-Copeland, C., Salifu, H., Jain, V., Singh, N., Stiles, J. (2013). CXCL10 gene promoter polymorphism -1447A>G correlates with plasma CXCL10 levels and is associated with male susceptibility to cerebral malaria. PLoS One, 8: e81329.

22. Wilson, N. O., Huang, M. B., Anderson, W., Bond, V., Powell, M., Thompson, W. E., Armah, H. B., Adjei, A. A., Gyasi, R., Tettey, Y., Stiles, J. K. (2008).Soluble factors from Plasmodium falciparum-infected erythrocytes induce apoptosis in human brain vascular endothelial and neuroglia cells. Mol Biochem Parasitol, 162: 172-176.

23. Sofroniew, M. V. (2015). Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci, 16: 249-263.

24. Rubio, N., Arevalo, M. A., Cerciat, M., Sanz-Rodriguez, F., Unkila, M., Garcia-Segura, L. M. (2014). Theiler's virus infection provokes the overexpression of genes coding for the chemokine Ip10 (CXCL10) in SJL/J murine astrocytes, which can be inhibited by modulators of estrogen receptors. J Neurovirol, 20: 485-495.

25. Hanke, M. L., Kielian, T. (2011). Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci (Lond), 121: 367-387.

26. McCarthy, G. M., Bridges, C. R., Blednov, Y. A., Harris, R. A. (2017). CNS cell-type localization and LPS response of TLR signaling pathways. F1000Res, 6: 1144-1168.

27. Eriksson, E. M., Sampaio, N. G., Schofield, L. (2013). Toll-Like Receptors and Malaria – Sensing and Susceptibility. J Trop Dis, 2(1): 126-133.

28. Knicke, K., Lingel, H., Chamaon, K., Brunner-Weinzierl, M. C. (2012). Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. PLoS One, 7: e31391.